• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Eledon Pharmaceuticals Inc.

    11/5/24 4:17:26 PM ET
    $ELDN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ELDN alert in real time by email
    SC 13G 1 tm2427451d2_sc13g.htm SC 13G

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. )*

     

    Eledon Pharmaceuticals, Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

     

    28617K101

    (CUSIP Number)

     

     

    October 29, 2024

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨Rule 13d-1(b)

     

    xRule 13d-1(c)

     

    ¨Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No.   28617K101

     

    1 Names of Reporting Persons
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    RA Capital Management, L.P.  
    2 Check the Appropriate Box if a Member of a Group (See Instructions)
    (a)
    ¨
    (b)
    ¨
    3

    SEC Use Only

     

    4 Citizenship or Place of Organization

    Delaware  

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH  
    5 Sole Voting Power

    0  
    6 Shared Voting Power

    3,566,338 
    7 Sole Dispositive Power

    0  
    8 Shared Dispositive Power

    3,566,338  

    9 Aggregate Amount Beneficially Owned by Each Reporting Person

    3,566,338  
    10 Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
    11 Percent of Class Represented by Amount in Row (9)

    6.1%  
    12 Type of Reporting Person (See Instructions)

    IA, PN  

      

     

     

     

    CUSIP No.   28617K101

     

    1 Names of Reporting Persons
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    Peter Kolchinsky
    2 Check the Appropriate Box if a Member of a Group (See Instructions)
    (a)
    ¨
    (b)
    ¨  
    3

    SEC Use Only

     

    4 Citizenship or Place of Organization

    United States  

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH  
    5 Sole Voting Power

    0  
    6 Shared Voting Power

    3,566,338  
    7 Sole Dispositive Power

    0  
    8 Shared Dispositive Power

    3,566,338  

    9 Aggregate Amount Beneficially Owned by Each Reporting Person

    3,566,338  
    10 Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
    11 Percent of Class Represented by Amount in Row (9)

    6.1%  
    12 Type of Reporting Person (See Instructions)

    HC, IN

     

     

     

     

    CUSIP No.   28617K101

     

    1 Names of Reporting Persons
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    Rajeev Shah
    2 Check the Appropriate Box if a Member of a Group (See Instructions)
    (a)
    ¨
    (b)
    ¨  
    3

    SEC Use Only

     

    4 Citizenship or Place of Organization

    United States  

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH  
    5 Sole Voting Power

    0  
    6 Shared Voting Power

    3,566,338  
    7 Sole Dispositive Power

    0  
    8 Shared Dispositive Power

    3,566,338  

    9 Aggregate Amount Beneficially Owned by Each Reporting Person

    3,566,338  
    10 Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
    11 Percent of Class Represented by Amount in Row (9)

    6.1%  
    12 Type of Reporting Person (See Instructions)

    HC, IN

     

     

     

     

    CUSIP No.   28617K101

     

    1 Names of Reporting Persons
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    RA Capital Healthcare Fund, L.P.
    2 Check the Appropriate Box if a Member of a Group (See Instructions)
    (a)
    ¨
    (b)
    ¨  
    3

    SEC Use Only

     

    4 Citizenship or Place of Organization

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH  
    5 Sole Voting Power

    0  
    6 Shared Voting Power

    3,566,338
    7 Sole Dispositive Power

    0  
    8 Shared Dispositive Power

    3,566,338

    9 Aggregate Amount Beneficially Owned by Each Reporting Person

    3,566,338  
    10 Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
    11 Percent of Class Represented by Amount in Row (9)

    6.1%  
    12 Type of Reporting Person (See Instructions)

    PN

     

     

     

     

    Item 1(a).Name of Issuer:

     

    Eledon Pharmaceuticals, Inc. (the “Issuer”)

      

    Item 1(b).Address of Issuer’s Principal Executive Offices:

     

    19800 MacArthur Blvd., Suite 250, Irvine, CA 92612

      

    Item 2(a).Names of Persons Filing:

     

    The names of the persons filing this report (collectively, the “Reporting Persons”) are:

     

    RA Capital Management, L.P. (“RA Capital”)

     

    Peter Kolchinsky

     

    Rajeev Shah

     

    RA Capital Healthcare Fund, L.P. (the “Fund”)

      

    Item 2(b).Address of Principal Business Office or, if None, Residence:

     

    The address of the principal business office of each of the Reporting Persons is:

     

    c/o RA Capital Management, L.P., 200 Berkeley Street, 18th Floor, Boston MA 02116

     

    Item 2(c).Citizenship:

     

    RA Capital and the Fund are Delaware limited partnerships.

    Dr. Kolchinsky and Mr. Shah are United States citizens.

     

    Item 2(d).Title of Class of Securities:

     

    Common Stock, par value $0.001 per share (“Common Stock”)

     

    Item 2(e).CUSIP Number:

     

    28617K101

      

    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    Not applicable.

     

    Item 4.Ownership.

     

    The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover pages to this Schedule 13G. The ownership percentages reported are based upon the sum of (i) 39,655,702 shares of Common Stock outstanding as of August 14, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on August 19, 2024; and (ii) 18,356,173 shares of Common Stock issued in the Issuer’s public offering of equity securities that closed on October 30, 2024.

     

    The Fund directly holds 3,566,338 shares of Common Stock.

     

     

     

     

    RA Capital Healthcare Fund GP, LLC is the general partner of the Fund. The general partner of RA Capital is RA Capital Management GP, LLC, of which Dr. Kolchinsky and Mr. Shah are the controlling persons. RA Capital serves as investment adviser for the Fund and may be deemed a beneficial owner, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended (“Act”), of any securities of the Issuer held by the Fund. The Fund has delegated to RA Capital the sole power to vote and the sole power to dispose of all securities held in the Fund’s portfolio, including the shares of the Issuer’s Common Stock reported herein. Because the Fund has divested voting and investment power over the reported securities it holds and may not revoke that delegation on less than 61 days’ notice, the Fund disclaims beneficial ownership of the securities it holds for purposes of Section 13(d) of the Act and therefore disclaims any obligation to report ownership of the reported securities under Section 13(d) of the Act. As managers of RA Capital, Dr. Kolchinsky and Mr. Shah may be deemed beneficial owners, for purposes of Section 13(d) of the Act, of any securities of the Issuer beneficially owned by RA Capital. RA Capital, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of the securities reported in this Schedule 13G other than for the purpose of determining their obligations under Section 13(d) of the Act, and the filing of this Schedule 13G shall not be deemed an admission that either RA Capital, Dr. Kolchinsky, or Mr. Shah is the beneficial owner of such securities for any other purpose.

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10.Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     

     

     

    Exhibit List

     

    Exhibit 1:Joint Filing Agreement

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of its or his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Dated: November 5, 2024

      

    RA CAPITAL MANAGEMENT, L.P.

     

    By: /s/ Peter Kolchinsky  
      Name: Peter Kolchinsky  
      Title: Authorized Signatory  

     

    PETER KOLCHINSKY

     

    /s/ Peter Kolchinsky  

     

    RAJEEV SHAH

     

    /s/ Rajeev Shah  

     

    RA CAPITAL HEALTHCARE FUND, L.P.

     

    By: RA Capital Healthcare Fund GP, LLC  
    Its: General Partner  
       
    By: /s/ Peter Kolchinsky  
      Name: Peter Kolchinsky  
      Title: Manager  

     

     

     

    Get the next $ELDN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ELDN

    DatePrice TargetRatingAnalyst
    1/28/2025$9.00Buy
    Guggenheim
    5/13/2022$25.00 → $15.00Overweight
    Cantor Fitzgerald
    11/24/2021$35.00 → $25.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $ELDN
    Leadership Updates

    Live Leadership Updates

    See more
    • Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results

      Enrolled 12 participants in Phase 2 BESTOW trial evaluating tegoprubart for the prevention of kidney rejection Tegoprubart used as a component of the immunosuppressive treatment regimen following the first-ever transplant of a kidney from a genetically modified pig to a human Additional data from 11 participants in Phase 1b trial in kidney transplantation demonstrated that tegoprubart was generally safe and well tolerated, successfully prevented rejection and permitted above historical average post-transplant kidney function IRVINE, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today reported its fourth quarter and full year 2023 opera

      3/28/24 4:01:00 PM ET
      $ELDN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 Outlook

      Reported updated data from ongoing Phase 1b trial in kidney transplantation demonstrating tegoprubart treatment successfully prevented kidney transplant rejection and was generally safe and well-tolerated  Dosed first participants in Phase 2 BESTOW trial in kidney transplantation  Tegoprubart dosed in second-ever pig to human xenotransplant procedure IRVINE, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced a summary of 2023 accomplishments and provided guidance for anticipated upcoming 2024 milestones. 2023 Key Highlights Reported updated data from ongoing Phase 1b trial evaluating tegoprubart for prevention of rejection i

      1/4/24 4:40:44 PM ET
      $ELDN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Eledon Pharmaceuticals Reports Third Quarter 2023 Operating and Financial Results

      Reported updated data from ongoing Phase 1b trial further supporting the potential of tegoprubart as a novel kidney transplant immunosuppressive therapy to prevent rejection and better preserve organ function First participant dosed in Phase 2 BESTOW trial evaluating tegoprubart for the prevention of rejection in kidney transplantation IRVINE, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today reported its third quarter operating and financial results and reviewed recent business highlights. "We were thrilled recently to report updated results from our ongoing Phase 1b study that continue to validate tegoprubart's potential as an immuno

      11/9/23 4:01:00 PM ET
      $ELDN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELDN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Eledon Pharmaceuticals Reports First Quarter 2025 Operating and Financial Results

      On track to report topline results from Phase 2 BESTOW trial in kidney transplantation in fourth quarter of 2025 Tegoprubart used as a key component of immunosuppression regimen in its second transplant of a genetically modified pig kidney into a human conducted at Massachusetts General Hospital Cash, cash equivalents and short-term investments of $124.9 million as of March 31, 2025 IRVINE, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today reported its first quarter 2025 operating and financial results and reviewed recent business highlights. "We continue to work diligently towards our goal of transforming the transplant treatm

      5/14/25 4:01:00 PM ET
      $ELDN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Operating and Financial Results

      Tegoprubart used as a key component of immunosuppression regimen in the second transplant of a genetically modified pig kidney into a human conducted at Massachusetts General Hospital Announced positive initial data from first three subjects with type 1 diabetes treated with tegoprubart as part of immunosuppression regimen following islet transplantation in investigator-initiated trial at UChicago Medicine Topline results from Phase 2 BESTOW trial of tegoprubart in kidney transplantation expected in fourth quarter of 2025 Proceeds from oversubscribed $85 million underwritten offering extend cash runway to end of 2026 IRVINE, Calif., March 20, 2025 (GLOBE NEWSWIRE) -- El

      3/20/25 4:01:00 PM ET
      $ELDN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Eledon Pharmaceuticals to Participate in Leerink Partners Global Healthcare Conference

      IRVINE, Calif., March 04, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced that Steve Perrin, Ph.D., Chief Scientific Officer and President, will participate in a fireside chat at the upcoming Leerink Partners Global Healthcare Conference on Tuesday, March 11, 2025, at 2:20 p.m. ET (11:20 a.m. PT). To register in advance for the fireside chat webcast, sign up here. A webcast replay will be accessible following the live session on the Company's website under Events. About Eledon Pharmaceuticals and tegoprubart Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the managem

      3/4/25 4:05:00 PM ET
      $ELDN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELDN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Executive Officer Gros David-Alexandre C

      4 - Eledon Pharmaceuticals, Inc. (0001404281) (Issuer)

      1/13/25 5:30:09 PM ET
      $ELDN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Kirk Allan

      4 - Eledon Pharmaceuticals, Inc. (0001404281) (Issuer)

      1/13/25 5:30:03 PM ET
      $ELDN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by President Perrin Steven

      4 - Eledon Pharmaceuticals, Inc. (0001404281) (Issuer)

      1/13/25 5:30:06 PM ET
      $ELDN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELDN
    SEC Filings

    See more
    • SEC Form 10-Q filed by Eledon Pharmaceuticals Inc.

      10-Q - Eledon Pharmaceuticals, Inc. (0001404281) (Filer)

      5/14/25 5:00:27 PM ET
      $ELDN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Eledon Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Eledon Pharmaceuticals, Inc. (0001404281) (Filer)

      5/14/25 4:05:53 PM ET
      $ELDN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Eledon Pharmaceuticals Inc.

      DEFA14A - Eledon Pharmaceuticals, Inc. (0001404281) (Filer)

      4/29/25 5:05:04 PM ET
      $ELDN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELDN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Guggenheim initiated coverage on Eledon Pharmaceuticals with a new price target

      Guggenheim initiated coverage of Eledon Pharmaceuticals with a rating of Buy and set a new price target of $9.00

      1/28/25 7:12:35 AM ET
      $ELDN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald resumed coverage on Eledon Pharmaceuticals with a new price target

      Cantor Fitzgerald resumed coverage of Eledon Pharmaceuticals with a rating of Overweight and set a new price target of $15.00 from $25.00 previously

      5/13/22 9:03:12 AM ET
      $ELDN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Eledon Pharmaceuticals with a new price target

      HC Wainwright & Co. reiterated coverage of Eledon Pharmaceuticals with a rating of Buy and set a new price target of $25.00 from $35.00 previously

      11/24/21 6:14:26 AM ET
      $ELDN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELDN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Eledon Pharmaceuticals Inc.

      SC 13G/A - Eledon Pharmaceuticals, Inc. (0001404281) (Subject)

      11/14/24 4:51:31 PM ET
      $ELDN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Eledon Pharmaceuticals Inc.

      SC 13G - Eledon Pharmaceuticals, Inc. (0001404281) (Subject)

      11/5/24 4:17:26 PM ET
      $ELDN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Eledon Pharmaceuticals Inc.

      SC 13G - Eledon Pharmaceuticals, Inc. (0001404281) (Subject)

      11/5/24 11:44:57 AM ET
      $ELDN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELDN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Bvf Partners L P/Il bought 1,927,937 shares (SEC Form 4)

      4 - Eledon Pharmaceuticals, Inc. (0001404281) (Issuer)

      5/13/24 5:04:15 PM ET
      $ELDN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELDN
    Financials

    Live finance-specific insights

    See more
    • Eledon Reports Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation

      Data from 11 participants demonstrates tegoprubart successfully prevented kidney transplant rejection and was generally safe and well-tolerated Aggregate mean eGFR was above 70 mL/min/1.73m2 at all reported time points after day 90 supporting tegoprubart's potential to protect organ function in patients undergoing kidney transplantation Eledon will host a conference call today at 5:00 p.m. ET IRVINE, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today reported results from the Company's ongoing Phase 1b open-label trial evaluating tegoprubart for the prevention of rejection in patients undergoing de novo kidney transplantation. Results

      11/2/23 9:05:00 AM ET
      $ELDN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Eledon Pharmaceuticals Reports First Quarter 2023 Operating and Financial Results

      Reported open-label data from ongoing Phase 1b trial of tegoprubart in kidney transplantation demonstrating mean eGFRs from 3 participants above 70 mL/min/1.73m2 at measured timepoints Completed financing of up to $185 million, with $35 million upfront, to fund the Company through the Phase 2 BESTOW kidney transplant trial, subject to achieving specific milestones Conference call today at 4:30 p.m. ET IRVINE, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today reported its first quarter operating and financial results and reviewed recent business highlights. "Eledon made significant progress this year in advancing the clinical developmen

      5/11/23 4:01:00 PM ET
      $ELDN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Eledon Pharmaceuticals to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023

      IRVINE, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced that it plans to release financial results for the first quarter ended March 31, 2023 on Thursday, May 11, after the close of trading. Eledon's management team will host a conference call and webcast beginning at 4:30 p.m. ET. Conference Call and Webcast Details: Thursday, May 11, 2023 at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific TimeToll Free: 888-886-7786International: 416-764-8658Conference ID: 11107025Webcast: https://ir.eledon.com/events-and-presentations/events After the live webcast, the event will be archived on Eledon's website for one year. About Eledon Phar

      5/4/23 4:05:00 PM ET
      $ELDN
      Biotechnology: Pharmaceutical Preparations
      Health Care